Category: 1162054-86-5

On May 10, 2017, Chen, Anjun; Sun, Fei; Yang, Wenlong; Xu, Ge; Zou, Chen published a patent.Recommanded Product: 1162054-86-5 The title of the patent was Method for preparing amino ether compound. And the patent contained the following:

The invention belongs to the tech. field of organic synthesis, and relates to a method for preparing amino ether compound The method comprises the steps of: protecting amino in amino alc. as raw material to obtain Schiff base, then etherifying hydroxy in Schiff base, and performing deprotection to the amino group to obtain corresponding amino ether. The method has high regioselectivity, more than 99.9% of the substrate is etherified, conversion ratio of every reaction is higher than 99.8%, and total yield is greater than 95. When amino alc. is chiral, amino ether with retention of configuration can be obtained. The method has the advantages of conventional operation, low process cost, few three wastes, low energy consumption, and being environment-friendly and easy for industrial large-scale production The experimental process involved the reaction of (S)-1-Methoxypropan-2-amine hydrochloride(cas: 1162054-86-5).Recommanded Product: 1162054-86-5

The Article related to amino ether preparation etherification, Aliphatic Compounds: Ethers and Sulfides and other aspects.Recommanded Product: 1162054-86-5

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On July 2, 2009, Kutzki, Olaf; Ditrich, Klaus; Bartsch, Michael published a patent.Category: ethers-buliding-blocks The title of the patent was Preparation of (s)-2-amino-1-propanol (l-alaninol) from (s)-1-methoxy-2-propylamine. And the patent contained the following:

The invention relates to a method for producing (S)-2-amino-1-propanol (L-alaninol) from (S)-1-methoxy-2-propylamine via the hydrochlorination of (S)-2-amino-1-propanol. Thus, (S)-1-methoxy-2-propylamine 53.5 g was reacted with 37% hydrochloric acid 148 g at 30-135�in N2 atmosphere at 19-30 bar for 4 h to give a viscous oily liquid at (S)-2-Amino-1-propanol hydrochloride. The experimental process involved the reaction of (S)-1-Methoxypropan-2-amine hydrochloride(cas: 1162054-86-5).Category: ethers-buliding-blocks

The Article related to methoxypropylamine hydrochloric acid aminopropanol preparation, Industrial Organic Chemicals, Leather, Fats, and Waxes: Manufacture Of Industrial Organic Chemicals and other aspects.Category: ethers-buliding-blocks

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On June 25, 2009, Chen, Li; Dillon, Michael Patrick; Feng, Lichun; Hawley, Ronald Charles; Yang, Minmin published a patent.Application of 1162054-86-5 The title of the patent was Preparation of imidazole-substituted arylamides as P2X3 and P2X2/3 antagonists for disease treatment. And the patent contained the following:

Compounds of the formula I (wherein R1 is (un)substituted imidazolyl; R2 is Ph, pyridinyl, pyrimidinyl, etc., all optionally substituted; R3 is H, C1-6-alkyl, hetero-C1-6-alkyl, or CN; R4 is H, C1-6-alkyl, or hetero-C1-6-alkyl; or R3 and R4 together form part of a ring; R5 is C1-6alkyl, hetero-C1-6alkyl; halo-C1-6alkyl, etc.; or R3, R4, and R5 together form part of a ring; and R6, R7 and R8 are independently H, C1-6-alkyl, C1-6-alkyloxy, halo, C1-6-haloalkyl, or CN) are provided herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds More particularly I are usable for treatment of genitourinary, pain, inflammatory, gastrointestinal and respiratory diseases, conditions and disorders. Example compound II was prepared by reacting imidazole with the appropriate 5-iodobiphenylcarboxamide intermediate. In a P2X3 FLIPR (fluorometric imaging plate reader) assay, example compound III had a pIC50 of approx. 8.55 for the P2X3 receptor. The experimental process involved the reaction of (S)-1-Methoxypropan-2-amine hydrochloride(cas: 1162054-86-5).Application of 1162054-86-5

The Article related to imidazole arylamide preparation p2x3 p2x2 receptor antagonist disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Application of 1162054-86-5

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On February 16, 2017, Pourashraf, Mehrnaz; Jacquemot, Guillaume; Claridge, Stephen; Bayrakdarian, Malken; Johnstone, Shawn; Albert, Jeffrey S.; Griffin, Andrew published a patent.Safety of (S)-1-Methoxypropan-2-amine hydrochloride The title of the patent was Substituted benzimidazoles as bromodomain inhibitors, their preparation and their use as pharmaceuticals. And the patent contained the following:

This application relates to substituted benzimidazoles of formula I, compositions comprising them and their uses in the treatment of diseases and conditions in which inhibition of a bromodomain is indicated. The application also relates to the treatment or prevention of proliferative disorders, auto-immune disorders, inflammatory disorders, dermal disorders, and neoplasm. Compounds of formula I wherein R1 is (un)substituted C1-6 alkyl, COR11, CONHR11, SO2R11, etc.; R2 is H, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl etc.; R3 and R6 are independently H, (un)substituted C1-6 alkyl, COR11, NH2 and derivatives, CONH2 and derivatives, etc.; one of R4 and R5 is H, (un)substituted C1-6 alkyl, COR11, NH2 and derivatives, CONH2 and derivatives, etc., and the other one of R4 and R5 is 6-membered nitrogen containing heterocycle; R11 is (un)substituted C1-6 alkyl;and pharmaceutically acceptable salts, solvates, esters and prodrugs thereof, are claimed. Example compound II was prepared by amidation of tetrahydropyran-4-carbonyl chloride with 4-bromo-N2-[2-(trifluoromethoxy)ethyl]benzene-1,2-diamine followed by cyclization; the resulting 6-bromo-2-tetrahydropyran-4-yl-1-[2-(trifluoromethoxy)ethyl]benzimidazole underwent cross-coupling reaction with 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-one to give compound II. The invention compounds were evaluated for their bromodomain inhibitory activity. From the assay, it was determined that compound II exhibited IC50 values in the range of 0.076 μM to 0.14 μM. The experimental process involved the reaction of (S)-1-Methoxypropan-2-amine hydrochloride(cas: 1162054-86-5).Safety of (S)-1-Methoxypropan-2-amine hydrochloride

The Article related to benzimidazole preparation bromodomain inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Safety of (S)-1-Methoxypropan-2-amine hydrochloride

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On March 7, 2013, Chen, Shaoqing; De Vicente Fidalgo, Javier; Hamilton, Matthew Michael; Hermann, Johannes Cornelius; Kennedy-Smith, Joshua; Li, Hongju; Lovey, Allen John; Lucas, Matthew C.; Luk, Kin-Chun Thomas; Lynch, Stephen M.; O’Yang, Counde; Padilla, Fernando; Schoenfeld, Ryan Craig; Sidduri, Achyutharao; Soth, Michael; Wang, Ce; Wovkulich, Peter Michael; Zhang, Xiaohu published a patent.Safety of (S)-1-Methoxypropan-2-amine hydrochloride The title of the patent was Pyrrolopyrazines as kinase inhibitors and their preparation. And the patent contained the following:

The invention relates to the use of pyrrolopyrazine derivatives of formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases. Compounds of formula I wherein R is H; R’ is lower alkoxy and (un)substituted alkyl; RR’ can be taken together to form (un)substituted heterocycloalkyl; Q is (un)substituted bicyclic heteroaryl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). All the invention compounds were evaluated for their kinase inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 0.00172 μM. The experimental process involved the reaction of (S)-1-Methoxypropan-2-amine hydrochloride(cas: 1162054-86-5).Safety of (S)-1-Methoxypropan-2-amine hydrochloride

The Article related to pyrrolopyrazine preparation kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of (S)-1-Methoxypropan-2-amine hydrochloride

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On June 17, 2010, Chen, Li; Feng, Lichun; Yang, Minmin; Dillon, Michael Patrick; Lai, Yingjie published a patent.Application In Synthesis of (S)-1-Methoxypropan-2-amine hydrochloride The title of the patent was Preparation of thiadiazole-substituted arylamides as P2X3 and P2X2/3 antagonists for treatment of pain and urinary tract disease. And the patent contained the following:

Compounds of the formula I (wherein R1 is (un)substituted thiadiazolyl; R2 is (un)substituted Ph, (un)substituted pyridinyl, (un)substituted pyrimidinyl, etc.; R3 is H, C1-6alkyl, or CN; R4 is H or C1-6alkyl; or R3 and R4 together with the atom to which they are attached may form a C3-6 carbocyclic ring; R5 is C1-6alkyl, C1-6alkoxy-C1-6alkyl, hydroxy-C1-6alkyl, etc.; or R4 and R5 together form part of a ring; or R3, R4, and R5 together form part of ring; R6, R7 and R8 are independently H, C1-6alkyl, C1-6alkyloxy, etc.) or a pharmaceutically acceptable salt thereof, are disclosed. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptors and methods of making the compounds Example compound II, prepared in a multistep reaction that culminated in the reaction of 3-(4-isopropyl-[1,2,3]thiadiazol-5-yl)-5-(5-methylpyridin-2-yl)benzoic acid and C-(5-methylpyrazin-2-yl)methylamine, had pKi values of 8.04 and 7.43 for P2X3 and P2X2/3 receptors, resp. The experimental process involved the reaction of (S)-1-Methoxypropan-2-amine hydrochloride(cas: 1162054-86-5).Application In Synthesis of (S)-1-Methoxypropan-2-amine hydrochloride

The Article related to thiadiazole arylamide preparation p2x3 p2x2 antagonist pain urinary disease, Heterocyclic Compounds (More Than One Hetero Atom): Other 5-Membered Rings, Two Or More Hetero Atoms and other aspects.Application In Synthesis of (S)-1-Methoxypropan-2-amine hydrochloride

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On May 14, 2020, Konradi, Andrei W.; Lin, Tracy Tzu-Ling Tang published a patent.Safety of (S)-1-Methoxypropan-2-amine hydrochloride The title of the patent was Preparation of substituted naphthalene-2-carboxamide derivatives useful for treatment of cancer. And the patent contained the following:

Provided herein are compounds of formula I and pharmaceutical compositions comprising said compounds that are useful for treating cancers specifically cancers that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD. Compounds of formula I [wherein X1 and X2 independently = N, NRx, C(=O), or CRx; X3, and X4 independently = N, NRx, C(=O), or CRx, with proviso; each Rx independently = H, halo, nitro, oxo, thioxo, (un)substituted C1-6 alkyl, (un)substituted (hetero)aryl, etc.; R1 = (un)substituted C1-6 alkyl, (un)substituted C1-6 haloalkyl, (un)substituted C3-10 cycloalkyl, etc.; each R2 independently = N3, CN, (un)substituted (hetero)aryl, etc.; n = 0, 1, 2, 3, or 4; each dashed line independently = single or double bond] or pharmaceutically acceptable salts or solvates thereof, are claimed and exemplified. Example compound II was synthesized from a multistep preparation starting from the bromination of 2-naphthylcarboxylic acid (preparation given). Exemplified I were evaluated in a YAP reporter assay from which II demonstrated an IC50 of ≤0.100μM against firefly luciferase activity. The experimental process involved the reaction of (S)-1-Methoxypropan-2-amine hydrochloride(cas: 1162054-86-5).Safety of (S)-1-Methoxypropan-2-amine hydrochloride

The Article related to naphthalene carboxamide derivative preparation cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of (S)-1-Methoxypropan-2-amine hydrochloride

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On January 7, 2016, Miyanaga, Wataru; Kawahira, Mizuki; Matsumoto, Kayo; Nakagawa, Tadakiyo; Tokumasu, Munetaka; Takeshita, Sen published a patent.SDS of cas: 1162054-86-5 The title of the patent was Preparation of heterocyclic amidocarboxylic acid compounds as glycogen synthase activators and pharmaceutical compositions containing them. And the patent contained the following:

The purpose of the present invention is to provide a novel compound that is capable of activating glycogen synthase but hardly activates receptor PPAR and shows high safety. Provided is a compound represented by general formula I (all variables are defined in the specification) or a pharmaceutically acceptable salt thereof. Thus, 2-[[5-[[4-(4,5-difluoro-2-methylsulfanylphenyl)phenoxy]methyl]furan-2-carbonyl]-(2-methoxyethyl)amino]acetic acid (preparation given) activated human glycogen synthase with EC50 <0.003 渭M. The experimental process involved the reaction of (S)-1-Methoxypropan-2-amine hydrochloride(cas: 1162054-86-5).SDS of cas: 1162054-86-5

The Article related to heterocyclic amidocarboxylic acid compound glycogen synthase activator treatment diabetes, phenylphenoxymethylfuranecaraboxamidoacetic acid preparation glycogen synthase activator and other aspects.SDS of cas: 1162054-86-5

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem